37% of ACOs are taking on downside risk

More accountable care organizations are taking on downside financial risk in the Medicare Shared Savings Program than ever before, with 37% in the program today participating in these arrangements.

This is a notable increase in the number of downside-risk ACOs, according to an analysis from Avalere Health. By comparison, just 10% of ACOs assumed downside risk annually from 2012 to 2017.

The increase is due to an overhaul of the MSSP, after CMS required ACOs to assume downside financial risk in their arrangements after just two years of participation, as opposed to six years previously. The vast majority of ACOs under the old rules participated as only taking upside risk, meaning they would share in financial savings but not have to pay back any financial losses to Medicare. However, the rule changes also led fewer ACOs to participate in 2020 and 2019.

The increase in downside risk also came from more experienced ACOs, as they tend to do better the longer they participate and are more likely to take on downside risk.

Since the level of ACOs with downside risk has remained low for many years, the impact of more arrangement with financial risk is yet to be determined.

“It remains undetermined if downside risk will create the appropriate incentives to reduce Medicare costs,” the analysis reads. “As the growth in downside-risk ACOs continue, future results will provide insight into whether risk is a meaningful factor in ACO success.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.